The COVID-19 pandemic has profound adverse effects on the population on dialysis.
Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality …

With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
pandemic, several vaccines have been developed to mitigate its spread and prevent …

The effects of the coronavirus disease-2019 (COVID-19) pandemic, particularly among
those with chronic kidney disease (CKD), who commonly have defects in humoral and …

Background Preliminary evidence suggests patients on hemodialysis have a blunted early
serological response to SARS-CoV-2 vaccination. Optimizing the vaccination strategy in this …

Importance Adults receiving dialysis treatment have a higher likelihood of death when
infected with SARS-CoV-2 than adults not receiving dialysis treatment. To date, the immune …

Introduction COVID-19 vaccine efficacy has been evaluated in large clinical trials and in real-
world situation. Although they have proven to be very effective in the general population …

Background Humoral response against sudden acute respiratory syndrome coronavirus 2
(SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less …

Background Vaccination studies in the hemodialysis population have demonstrated
decreased antibody response compared with healthy controls, but vaccine effectiveness for …

End‐stage renal disease (ESRD) patients are amongst the vulnerable groups and thus
prioritized in the Coronavirus disease‐2019 vaccination programmes. However, this cohort …

Background In a country-wide seroprevalence study of COVID-19 in Estonia, we aimed to
determine the seroprevalence and the dynamics of IgG against SARS-CoV-2 after …